

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**”) dated 6 December 2021 in relation to the continuing connected transactions in respect of (i) the 2021 Healthcare Food and Food Purchase Framework Agreement; and (ii) 2021 Distribution Agreement (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (a) further information relating to the 2021 Healthcare Food and Food Purchase Framework Agreement and 2021 Distribution Agreement; (b) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders relating to the 2021 Healthcare Food and Food Purchase Framework Agreement and the 2021 Distribution Agreement; and (c) a letter from the Independent Board Committee to the Independent Shareholders relating to the 2021 Healthcare Food and Food Purchase Framework Agreement and the 2021 Distribution Agreement will be sent to the Shareholders as soon as possible.

As more time is required for the Company to prepare and finalise certain information to be included in the Circular, it is expected that the despatch of the Circular will be postponed to a date not later than 14 January 2022.

By order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, PRC, 28 December 2021

As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Xu Yan He; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material aspects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.

** For identification purpose only*